Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
HOME > ORGANIZATION
ORGANIZATION
- Generic Use Rate at 79.4% in FY2020, Up 2.5 Points: JGA
August 3, 2021
- New Industry Czar Vows to Balance Interests of Innovative Pharma, Gx Businesses as Budget Debate Creates Divide
July 30, 2021
- JPMA Reprimands Meiji Pharma over Kobayashi Kako Issue
July 16, 2021
- Hiroyuki Kawabata Joins PhRMA as Sr. Assistant Japan Representative
July 16, 2021
- Downloads of FPMAJ’s E-Labeling App on Track to Target 50,000 as Legal Enforcement Approaches
July 14, 2021
- Japan Patient Advocates Want Drugs for Later-Stage Alzheimer’s
July 13, 2021
- New Trade Group for Established Drugs to Launch in Japan
July 13, 2021
- FIRM Calls for Separate Pricing System for Regenerative Medicine Products: Chair
July 13, 2021
- JMA Frets Pricey Dementia Meds, to Explore Ways to Keep Universal Coverage
July 9, 2021
- High-Priced Drugs Should Be Discussed Carefully Based on Characteristics of Diseases and Treatments: JMA Exec
July 1, 2021
- More than 80% of Pharmacists Feel Impact of Generic Supply Delays on Business: Survey
June 23, 2021
- Patient Group Wants More R&D Spending on Pancreatic Cancer
June 15, 2021
- Saitama-Based Hospital Group Introduces Formulary in 18 Therapeutic Areas, Aims to Spread Know-How in Region
June 15, 2021
- FPMAJ Urges Caution with Market Expansion Re-Pricing, Says Add’l Indications Now Seen as Price Cut Risk
June 14, 2021
- FPMAJ Drug Price Report Rebuts Issues Raised over Cost-Plus Method, PMP and More
June 14, 2021
- PhRMA Posts Its Position on Japan CEA Scheme on Website
June 11, 2021
- Eisai’s Akana Re-Elected as FPMAJ’s Drug Pricing Chief
June 11, 2021
- Terumo’s Mimura Elected New Medical Devices Chief; Reimbursement Debate Ahead for SaMD
June 9, 2021
- Experts Eye Macroeconomic Indexing of Drug Costs to Keep Innovation Afloat: INES Proposal
May 31, 2021
- Ken Suzuki Returns to JPWA Reins after 2 Years
May 28, 2021
ページ
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…